Heart failure & cardiomyopathies
Association Between NT-Probnp Changes and Clinical Outcomes in Paediatric Patients with Heart Failure: Insights from PANORAMA-HF and PARADIGM-HF
Authors' conclusion
This is the first prospective, randomized large-scale study to demonstrate a strong correlation between NT-proBNP levels and risks of HF clinical events in paediatric patients with HF.
Study context
- Population
- Paediatric patients with left ventricular systolic dysfunction from Part 2 of the PANORAMA-HF trial, compared with a subset of adult heart failure with reduced ejection fraction (HFrEF) patients from the PARADIGM-HF trial
- Participants
- 361 paediatric patients
- Comparison
- Associations between baseline NT-proBNP levels, changes post-baseline and the risk of HF clinical events in paediatric patients on sacubitril/valsartan or enalapril
- Sacubitril/valsartann = 179
- Enalapriln = 182
Primary result
As reported in the abstract
Baseline NT-proBNP levels by age group
- Overall higher baseline NT-proBNP levels in younger age groups (AGs)
Further findings
NT-proBNP levels · Week 52
- Both treatment groups exhibited reduced NT-proBNP levels across all AGs
- Reductions were comparable between sacubitril/valsartan and enalapril, with a numerically greater reduction observed in adult patients versus children
Association between NT-proBNP levels and HF clinical events
- Doubling of NT-proBNP levels: increased risk of HF clinical events
- ≥1.7-fold
- Halving of NT-proBNP levels: reduction in the risk of clinical events
- 52%
- Strong associations between NT-proBNP levels and HF clinical outcomes in paediatric populations in PANORAMA-HF and in adult DCM patients with HFrEF in PARADIGM-HF
- Cox proportional hazard model
Original publication
Association Between NT-Probnp Changes and Clinical Outcomes in Paediatric Patients with Heart Failure: Insights from PANORAMA-HF and PARADIGM-HF. ESC Heart Fail. Published 12 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →